Overview

Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
To determine the safety and efficacy of a single dose of solithromycin (CEM-101) for the treatment of uncomplicated urogenital gonorrhea.
Phase:
Phase 2
Details
Lead Sponsor:
Cempra Inc
Melinta Therapeutics, Inc.
Treatments:
Solithromycin